CGX directly disrupts sympathetic nerve input by removing the sympathetic ganglia located at the root of the abdominal aorta, resulting in a marked reduction of sympathetic activity.[21] Similar to 6‐OHDA treatment, CGX significantly elevated diabetes incidence and mortality and lowered serum insulin levels in NOD mice (Figure 2I–K). This evidence concerns the gene INS and diabetes mellitus.